Skip to main content

Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF

Catalog # 10748-CV | R&D Systems, Inc. a Bio-Techne Brand
Alpha Variant (UK) Resistant to Furin & Stabilized Prefusion Conformation
Catalog #
Availability
Size / Price
Qty
Loading...
10748-CV-100

Key Product Details

Source

HEK293

Accession #

Conjugate

Unconjugated

Applications

Bioactivity

Product Specifications

Source

Human embryonic kidney cell, HEK293-derived sars-cov-2 Spike protein
Val16-Lys1211 (His69 del, Val70 del, Tyr145 del, Asn501Tyr, Ala570Asp, Asp614Gly, Pro681His, Thr716Ile, Ser982Ala, Asp1118His)(Arg682Ser, Arg685Ser, Lys986Pro, Val987Pro), with a C-terminal 6-His tag

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Protein identity is confirmed by mass spectrometry.

Predicted Molecular Mass

134 kDa

SDS-PAGE

148-166 kDa, under reducing conditions

Activity

Measured by its binding ability in a functional ELISA with Recombinant Human ACE-2 His-tag  (Catalog # 933-ZN).

Scientific Data Images for Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF

Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein Binding Activity.

Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag (Catalog # 10748-CV) binds Recombinant Human ACE-2 His-tag (933-ZN) in a functional ELISA.

Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein SDS-PAGE.

2 μg/lane of Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag (Catalog # 10748-CV) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 148-166 kDa.
Surface plasmon resonance (SPR) sensorgram of Human ACE-2 binding to UK variant B.1.1.7 Spike mutant protein

Binding of ACE-2 to UK variant B.1.1.7 Spike protein by surface plasmon resonance (SPR).

Recombinant SARS-CoV-2 Spike protein UK variant B.1.1.7 His-tag was immobilized on a Biacore Sensor Chip CM5, and binding to recombinant human ACE-2 (933-ZN) was measured at a concentration range between 0.18 nM and 94.3 nM. The double-referenced sensorgram was fit to a 1:1 binding model to determine the binding kinetics and affinity, with an affinity constant of KD=1.185 nM. (Biacore T200).

Formulation, Preparation and Storage

10748-CV
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 500 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Spike

SARS-CoV-2, which causes the global pandemic coronavirus disease 2019 (Covid-19), belongs to a family of viruses known as coronaviruses that are commonly comprised of four structural proteins: Spike protein (S), Envelope protein (E), Membrane protein (M), and Nucleocapsid protein (N) (1). SARS-CoV-2 Spike Protein (S Protein) is a glycoprotein that mediates membrane fusion and viral entry. The S protein is homotrimeric, with each ~180-kDa monomer consisting of two subunits, S1 and S2 (2). In SARS-CoV-2, as with most coronaviruses, proteolytic cleavage of the S protein into the S1 and S2 subunits is required for activation. The S1 subunit is focused on attachment of the protein to the host receptor while the S2 subunit is involved with cell fusion (3-5). The S protein of SARS-CoV-2 shares 75% and 29% amino acid (aa) sequence identity with the S protein of SARS-CoV-1 and MERS, respectively.The S Protein of the SARS-CoV-2 virus, like the SARS-CoV-1 counterpart, binds Angiotensin-Converting Enzyme 2 (ACE2), but with much higher affinity and faster binding kinetics through the receptor binding domain (RBD) located in the C-terminal region of S1 (6). Based on structural biology studies, the RBD can be oriented either in the up/standing or down/lying state with the up/standing state associated with higher pathogenicity (7). Polyclonal antibodies to the RBD of the SARS-CoV-2 protein have been shown to inhibit interaction with the ACE2 receptor, confirming RBD as an attractive target for vaccinations or antiviral therapy (8). It has been demonstrated that the S Protein can invade host cells through the CD147/EMMPRIN receptor and mediate membrane fusion (9, 10). A SARS-CoV-2 variant carrying the aa substitution N501Y in the RBD and nine additional mutations in the rest of the spike protein becomes one of the most prevalent mutations found in Covid-19 cases (11-13). This mutant (B.1.1.7 lineage) was originally found in London and the southeast UK but rapidly spread globally (8,9). This new virus variant was reported 56% more transmissible than other preexisting variants (14). The N501Y mutation was also later identified in variants found in South Africa (B.1.351 lineage) and Brazil (P.1 lineage). Although there is no evidence to date that B.1.1.7 causes more severe illness, whether the N501Y mutation in RBD would decrease the efficacy of vaccine-induced immunity is still under investigation.

References

  1. Wu, F. et al. (2020) Nature 579:265.
  2. Tortorici, M.A. and D. Veesler (2019). Adv. Virus Res. 105:93.
  3. Bosch, B.J. et al. (2003). J. Virol. 77:8801.
  4. Belouzard, S. et al. (2009) Proc. Natl. Acad. Sci. 106:5871.
  5. Millet, J.K. and G.R. Whittaker (2015) Virus Res. 202:120.
  6. Ortega, J.T. et al. (2020) EXCLI J. 19:410.
  7. Yuan, Y. et al. (2017) Nat. Commun. 8:15092.
  8. Tai, W. et al. (2020) Cell. Mol. Immunol. https://doi.org/10.1016/j.it.2020.03.007.
  9. Wang, X. et al. (2020) https://doi.org/10.1038/s41423-020-0424-9.
  10. Wang, K. et al. (2020) bioRxiv https://www.biorxiv.org/content/10.1101/2020.03.14.988345v1.
  11. Kozlov, Max (2020) TheScientist https://www.the-scientist.com/news-opinion/new-sars-cov-2-variant-spreading-rapidly-in-uk-68292.
  12. Wise, J. (2020) B.M.J. 371:m4857.
  13. Tang, J.W. et al. (2020) J. Infect. doi:10.1016/j.jinf.2020.12.024.
  14. Davies, N.G. (2020) medRxiv doi:10.1101/2020.12.24.20248822.

Long Name

Spike Protein

Alternate Names

S Protein

Entrez Gene IDs

918758 (HCoV-229E); 2943499 (HCoV-NL63); 39105218 (HCoV-OC43); 37616432 (MERS-CoV); 1489668 (SARS-CoV); 43740568 (SARS-CoV-2)

Gene Symbol

S

UniProt

Product Documents for Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF

For research use only

Citations for Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF (1)

Showing  1 - 1 of 1 publication Showing All
Filter By:
Search Title:

Citations are publications that use Bio-Techne products. Selected citations for Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF include:

There are no citations that match your criteria.

Showing  1 - 1 of 1 publication Showing All

FAQs for Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF

Showing  1 - 1 of 1 FAQ Showing All
  • Q: What is meant by "Resistant to Furin & Stabilized Prefusion Conformation?" in the description for Recombinant SARS-CoV-2 B.1.1.7 Spike His-tag Protein, CF (Catalog # 10748-CV)?

    A: Furin cleavage resistance is conferred by the Arg682Ser and Arg685Ser mutations. The mutations Lys986Pro and Val987Pro stabilize and promote the prefusion conformation of this Spike protein.

Showing  1 - 1 of 1 FAQ Showing All

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

÷
=
Loading...
Setting the standard in quality research reagents